Sorafenib is an oral multikinase inhibitor that acts by inhibiting tumor growth and disrupting
tumor microvasculature through antiproliferative, anti-angiogenic and proapoptotic effects. It …

Portal vein tumor thrombus (PVTT) usually worsens prognosis of hepatocellular carcinoma
(HCC), as characterized by aggressive disease progression, impaired liver function and …

Background The evidence of combining sorafenib with transarterial chemoembolization
(TACE) for intermediate-stage recurrent hepatocellular carcinoma (HCC) is limited. Patient …

Aim Until now, no effective adjuvant therapy to prevent early recurrence of hepatocellular
carcinoma (HCC) after curative treatment has been reported. The aim of this study is to …

AIM: To investigate the efficacy and safety of adjuvant sorafenib after curative resection for
patients with Barcelona Clinic Liver Cancer (BCLC)-stage C hepatocellular carcinoma …

Background Sorafenib was reported as a useful adjuvant treatment in patients with
hepatocellular carcinoma who underwent surgical resection. However, its therapeutic value …

Background: The prognosis of hepatocellular carcinoma (HCC) with tumor thrombus in the
major portal vein has been extremely poor. We investigated the outcome of hepatic …

Introduction: hepatocellular carcinoma (HCC) recurrence after liver resection remains a
major threat for patients' survival. Sorafenib is recommended as an adjuvant treatment for …

Importance Transarterial chemoembolization (TACE) is commonly used to treat patients with
recurrent intermediate-stage hepatocellular carcinoma (HCC) and positive microvascular …

Sorafenib is the standard systemic treatment for patients with advanced hepatocellular
carcinoma (HCC); however, its therapeutic value in patients with HCC following resection …